Clinical Trials in Newmarket, Ontario
51 recruiting
Showing 1–20 of 49 trials
Recruiting
Phase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Plaque Psoriasis
Bristol-Myers Squibb3,040 enrolled383 locationsNCT07116967
Recruiting
Phase 3
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Non-small Cell Lung Cancer
AstraZeneca675 enrolled283 locationsNCT06357533
Recruiting
Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1155 locationsNCT07064473
Recruiting
Phase 3
Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases
Cancer, Metastatic
Canadian Cancer Trials Group230 enrolled9 locationsNCT06391242
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC1,530 enrolled299 locationsNCT06393374
Recruiting
Not Applicable
The Fourth Left Atrial Appendage Occlusion Study
Atrial FibrillationStroke, IschemicSystemic Embolism
Hamilton Health Sciences Corporation4,000 enrolled140 locationsNCT05963698
Recruiting
Phase 2
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Non-segmental Vitiligo
Novartis Pharmaceuticals210 enrolled28 locationsNCT07431177
Recruiting
Phase 3
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Breast Neoplasms
Merck Sharp & Dohme LLC1,200 enrolled259 locationsNCT06312176
Recruiting
Phase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
Cardiovascular Disease
Amgen11,000 enrolled247 locationsNCT07136012
Recruiting
Phase 3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
Cardiovascular Disease
AstraZeneca15,100 enrolled1333 locationsNCT07000357
Recruiting
Phase 2Phase 3
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Stage III Colon Cancer
NRG Oncology1,912 enrolled1061 locationsNCT05174169
Recruiting
Not Applicable
RAFT - Pace &Ablate
Heart FailureAtrial FibrillationPacemaker+1 more
Habib Khan600 enrolled12 locationsNCT06299514
Recruiting
Phase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
ObesityHeart Failure With Preserved Ejection FractionHeart Failure With Mildly Reduced Ejection Fraction
Amgen5,056 enrolled605 locationsNCT07037459
Recruiting
Phase 3
A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)
Breast Neoplasm FemaleRadiotherapyCosmetic Outcome
Ontario Clinical Oncology Group (OCOG)910 enrolled29 locationsNCT05417516
Recruiting
Phase 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Heart Failure
AstraZeneca11,300 enrolled942 locationsNCT06677060
Recruiting
Phase 2
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
Atrial Fibrillation
Novartis Pharmaceuticals165 enrolled38 locationsNCT07217067
Recruiting
Phase 3
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Metastatic Non Small Cell Lung Cancer
AstraZeneca744 enrolled303 locationsNCT06417814
Recruiting
Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
AstraZeneca830 enrolled296 locationsNCT06868277
Recruiting
Phase 3
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
Multiple Myeloma
Canadian Cancer Trials Group570 enrolled28 locationsNCT06182774
Recruiting
Phase 2
LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma
Melanoma
Canadian Cancer Trials Group128 enrolled14 locationsNCT06623461